评估2级脑膜瘤的辅助放射治疗:一项多机构分析
这项多机构回顾性队列研究纳入2006至2020年新诊断的429例成人2级脑膜瘤患者,分析辅助放疗对无进展生存期的影响。全切除后辅助放疗与PFS无关(HR 0.85),次全切除后辅助放疗与PFS改善相关(HR 0.54),Ki67≥10%者辅助放疗与PFS改善相关(HR 1.89)。
要点
- 全切除后辅助放疗与无进展生存期无关(HR 0.85;95%CI 0.48-1.52)。
- 次全切除后辅助放疗与无进展生存期改善相关(HR 0.54;95%CI 0.31-0.94)。
- Ki67≥10%者辅助放疗与PFS改善相关(HR 1.89;95%CI 1.05-3.60;P=.034)。
核心结论
- 2级脑膜瘤辅助放疗可能减少Ki67指数≥10%或次全切除后患者的肿瘤进展,应作为多学科术后管理的一部分考虑。
- 全切除后常规使用辅助放疗与PFS改善无关,应考虑避免全切除后放疗以减少潜在治疗相关并发症。
- 本研究支持选择性使用辅助放疗,通过平衡减少进展的获益与潜在治疗并发症来优化患者结局。
研究设计与样本
- 多机构回顾性队列研究,纳入2006至2020年在Mass General Brigham医院新诊断且既往未治疗的2级脑膜瘤成人患者,共429例。
主要发现
- 共纳入429例2级脑膜瘤患者,中位年龄59.7岁,女性占61.5%。
- 298例(69.5%)实现全切除;284例有定量Ki67增殖指数,中位增殖指数为10.0%(IQR 6.7%-15%)。
- 全切除后18.8%的病例接受辅助放疗,次全切除后48.9%的病例接受辅助放疗;中位随访5.2年。
- 辅助放疗与全切除后PFS无关(HR 0.85;95%CI 0.48-1.52),但与次全切除后PFS改善相关(HR 0.54;95%CI 0.31-0.94);调整年龄、性别、肿瘤位置和肿瘤大小后结果一致。
- 辅助放疗与Ki67指数≥10%病例的PFS改善相关(HR 1.89;95%CI 1.05-3.60;P=.034),但与Ki67<10%病例的PFS无关(HR 0.94;95%CI 0.47-1.67;P=.93)。
临床怎么用
- 作者认为,2级脑膜瘤辅助放疗应作为多学科术后管理的一部分考虑,适用于Ki67指数≥10%或次全切除后的患者。
- 作者认为,全切除后应考虑避免辅助放疗以减少潜在治疗相关并发症。
- 作者认为,本研究支持选择性使用辅助放疗,以平衡减少进展的获益与潜在治疗并发症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Grade 2 meningiomas are associated with variable rates of local recurrence, and the role of adjuvant radiation therapy (RT) remains debated. METHODS: This was a multi-institutional retrospective cohort study including all adult patients with newly diagnosed and previously untreated grade 2 meningioma treated at Mass General Brigham hospitals from 2006 to 2020. Cox proportional-hazards modeling was used to analyze the impact of adjuvant RT on progression-free survival (PFS). RESULTS: A total of 429 patients with grade 2 meningioma were included (median age 59.7 years, 61.5% female). Gross total resection (GTR) was achieved in 298 cases (69.5%). Among 284 cases with quantified Ki67 proliferation indices, the median proliferation indice was 10.0% (IQR 6.7%-15%). In total, 18.8% cases had adjuvant RT after GTR and 48.9% of cases had adjuvant RT after subtotal resection (STR). The median follow-up was 5.2 years. Adjuvant RT was not associated with PFS after GTR (hazard ratio [HR] 0.85; 95% CI 0.48-1.52) but was associated with improved PFS after STR (HR 0.54; 95% CI 0.31-0.94). These findings remained consistent after adjusting for age, sex, tumor location, and tumor size. Adjuvant RT was associated with improved PFS for cases with Ki67 index equal to or over 10% (HR 1.89; 95% CI 1.05-3.60; P = .034), but not below 10% (HR 0.94; 95% 0.47-1.67; P = .93). CONCLUSION: Adjuvant RT for grade 2 meningioma may reduce tumor progression for patients with Ki67 index ≥10% or after STR and should be considered as part of a multidisciplinary approach to postoperative management. Routine use of adjuvant RT after GTR was not associated with improved PFS, for which avoidance of RT after GTR should be considered to minimize potential treatment-associated morbidity. This study supports selective use of adjuvant RT, optimizing patient outcomes by balancing the benefits of reduced progression against potential morbidities of treatment.
引用
- Gupta S, Arora H, Chavarro VS, et al. Evaluating Adjuvant Radiation Therapy for Grade 2 Meningioma: A Multi-Institutional Analysis. Neurosurgery. 2025. PMID: 40298374. doi:10.1227/neu.0000000000003469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。